

PolyCide[®] Antimicrobial Materials Fact Sheet

CORPORATE OVERVIEW

PolyMedix is a clinical stage biotechnology company developing first-in-class, small-molecule drugs for the treatment of acute care conditions. PolyMedix has created a robust pipeline of novel, innovative compounds targeting infectious diseases and cardiovascular conditions, based on its proprietary drug discovery platform.

In addition to its phase II therapeutic programs PolyMedix leverages its antibiotics expertise by developing PolyCide[®], synthetic antimicrobial materials for use in personal care articles, cosmetics, plastics, textiles and other materials to create self-sterilizing products and surfaces. PolyCide[®] kills microbes by targeting and destabilizing microbial cell membranes. This mechanism of action exists in nature in the form of host defense proteins and has been conserved in all higher organism throughout evolution as a response to ward off infection. PolyCide[®] is fast-acting and effective against many microbes, including antibiotic-resistant bacteria such as MRSA.

MANAGEMENT TEAM

Nicholas Landekic
President & CEO

Dr. Daniel Jorgensen
SVP Clinical Development & CMO


Dr. Bozena Korczak
SVP Drug Development & Chief Development Officer

Edward Smith
VP Finance & CFO

Dr. Richard Scott
VP Research

Dr. Steffen Helmling
VP Business Development

POLYCID[®] MECHANISM OF ACTION—DISRUPTION OF BACTERIAL MEMBRANE



Pictured above is a specimen of the bacterium *E. coli* before and after a minute exposure to one of PolyMedix's bactericidal compounds. PolyCide[®] selectively targets the microbial membrane by inserting and destabilizing the lipid layer of the membrane, leading to rapid cell death.

COMPANY INFORMATION

- Two first-in-class drugs in phase II clinical trials for indications with unmet medical need and large market opportunities
- Antimicrobial materials for non-therapeutic applications
- Broad intellectual property covering platform and composition of matter
- Robust pipeline
- Experienced management team
- Founded in 2002
- 28 employees
- Raised \$115 mm to date
- \$17 mm from NIH grants & defense contracts
- Public since 2006
OTC BB: PYMX

POLYCID[®] HIGHLIGHTS

- **Novel antimicrobial materials with superior properties**
- **Mechanism of action imitates natural immunity**
- **Mechanism of action reduces chance of bacterial resistance**
- **Broad-spectrum antimicrobial activity**
- **Effective against drug resistant bacteria such as MRSA**
- **High selectivity— less toxic than existing antimicrobials**
- **Fast acting—rapid bactericidal activity**
- **Compatible with many materials and formulations**
- **Creation of self-sterilizing surfaces, clothing, etc.**



PRODUCT APPLICATIONS

Biomedical:

- Catheters + IV tubing
- Wound dressings
- Implantable devices
- Surgical gloves

Industrial:


- Paint + antifouling coatings
- Hospital surfaces

Consumer products:

- Personal care + cosmetics
- Toys
- Textiles
- Carpeting

MATERIAL COMPATIBILITY

PolyCide[®] has been successfully incorporated into different materials, including PVC, polyurethane, polystyrene, etc. Illustrated below is the antibacterial effect of 1% PolyCide[®] in medical grade PVC: Bacterial growth on the PVC material (bottom left) is readily eliminated in the presence of 1% PolyCide[®] (right).




0% PolyCide[®]
Bacterial growth


1% PolyCide[®]
no growth

WHAT MAKES POLYCID[®] ANTIMICROBIAL?

PolyCide[®] is a group of synthetic compounds specifically designed to contain charged and hydrophobic faces. This amphiphilic molecular structure allows for a specific interaction with bacterial surfaces, leading to subsequent insertion into the membrane and its disruption. The structure and mechanism of PolyCide mimics host defense proteins, an evolutionary conserved part of the immune system to combat infection.



WHAT SETS POLYCID[®] APART?




RAPID BACTERICIDAL ACTIVITY

PolyCide[®] rapidly kills bacteria upon exposure. This is advantageous over silver-based technologies, which are bacteriostatic. In experiments with PolyCide[®]-treated surfaces, bacteria are killed within two minutes of exposure. Live cells are indicated by GREEN fluorescence; dead cells by RED fluorescence.

RESISTANCE UNLIKELY

Bacterial resistance to antibiotics is a growing threat to public health and is becoming increasingly widespread. The mechanism of action of PolyCide[®] makes bacterial resistance unlikely. In the laboratory no resistance has been found with PolyCide[®] in serial passage assays, but can be readily shown for common antibiotics (see right).



PolyMedix seeks licensing and development partners to commercialize PolyCide[®]

FOR FURTHER INFORMATION PLEASE CONTACT:

Steffen Helmling, PhD
 Vice President Business Development
 Phone: +1-484-598-2344
 Fax: +1-484-598-2401
 Email: shelmling@polymedix.com

Informational materials on PolyMedix may contain forward-looking statements, including regarding anticipated scientific progress in research programs and product development. Developing drugs is risky, expensive, and time-consuming. Delays typically occur in drug development and should be expected, and the actual pace of PolyMedix's development may be substantially delayed and materially differ from these goals and projections. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, PolyMedix does not intend (and it is not obligated) to update publicly any forward-looking statements. The information provided herein is not a solicitation for investment, nor an offering to sell any type of security in PolyMedix. Investing in PolyMedix or any security involves risk of loss. You should consult with a qualified financial advisor and other experts before making any investment decisions.